Clinical Trials Logo

Clinical Trial Summary

The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of Gram-Negative BloodStream Infection (GN-BSI) is as effective but safer than remaining on intravenous (IV) antibiotic therapy for the duration of treatment.


Clinical Trial Description

This is an open-label, pragmatic, randomized trial of approximately 1,204 adult patients hospitalized across 9 United States hospitals with the overarching goal of determining whether the optimal approach for the management of GN-BSI is (1) IV antibiotics for the duration of treatment or (2) initial IV antibiotics followed by early transition to oral antibiotics for the duration of treatment. Patients will be randomized in a 1:1 ratio to remain on IV antibiotics or transition to oral antibiotics as soon as possible after blood culture collection, but no more than 5 days later. The primary objective is to compare the Desirability of Outcomes Ranking (DOOR) distributions between patients with GN-BSI receiving IV antibiotic treatment only versus patients transitioned early to oral antibiotic treatment. The study hypothesis is that oral treatment will result in a more favorable DOOR distribution than IV treatment, likely as a result of differential adverse events and changes in Quality of Life (QoL) profiles. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06080698
Study type Interventional
Source Johns Hopkins University
Contact Pranita D Tamma, MD, MHS
Phone 410-614-1492
Email ptamma1@jhmi.edu
Status Recruiting
Phase N/A
Start date February 22, 2024
Completion date June 30, 2027

See also
  Status Clinical Trial Phase
Withdrawn NCT03745014 - Clinical Impact of Fast Phenotypic Antimicrobial Susceptibility Testing on Patients With Gram-Negative Rod Bacteremia N/A
Completed NCT03218397 - Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia N/A
Enrolling by invitation NCT04055922 - Comparison of Solid Organ Transplant
Recruiting NCT04291768 - Shortened Antibiotic Treatment of 5 Days in Gram-negative Bacteremia Phase 4
Not yet recruiting NCT06214403 - Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation Phase 2
Completed NCT05605275 - CRP and PCT as Predictors of Sepsis Cause
Completed NCT02599220 - Clinical Outcomes and Cost of Gram Negative Bacteremia N/A
Recruiting NCT06174649 - Fast Antibiotic Susceptibility Testing for Gram Negative Bacteremia Trial N/A
Recruiting NCT05893147 - BALANCE+ Vanguard Phase N/A